Stock Events

Stock Events

Phio Pharmaceuticals 

€53.99
55
-€0-0% Monday 20:00

Statistics

Day High
-
Day Low
-
52W High
53.99
52W Low
2.19
Volume
-
Avg. Volume
19
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-0.29
-0.24
-0.18
-0.13
Expected EPS
-0.20054665
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 44R0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap17.99B
Moderna is a leader in mRNA technology, competing in the broader field of genetic medicines, similar to Phio's RNAi therapeutics approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Phio's core technology and product pipeline.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.48B
Arrowhead Pharmaceuticals focuses on developing RNAi therapeutics for a variety of diseases, making it a direct competitor.
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, competing in the same space as Phio.
Sarepta Therapeutics
SRPT
Mkt Cap2.27B
Sarepta Therapeutics focuses on RNA-based therapies, particularly for rare diseases, overlapping with Phio's therapeutic areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, including RNA-based products, competing in the genetic disease market.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is focused on developing gene-based medicines, including CRISPR/Cas9 technology, which competes in the broader genetic medicine space.
Intellia Therapeutics
NTLA
Mkt Cap1.58B
Intellia Therapeutics is a leading developer of CRISPR gene editing, competing in the genetic medicine field alongside companies like Phio.

About

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Show more...
CEO
Mr. Robert J. Bitterman
Employees
5
Country
United States
ISIN
US71880W5013

Listings

MU
DE
44R0.MU
XNAS
US
PHIO
BOATS
BOATS
PHIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Phio Pharmaceuticals stock price today?▼
The current price of 44R0.MU is €53.99 EUR — it has decreased by -0% in the past 24 hours. Watch Phio Pharmaceuticals stock price performance more closely on the chart.
What is Phio Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Phio Pharmaceuticals stocks are traded under the ticker 44R0.MU.
Is Phio Pharmaceuticals stock price growing?▼
44R0.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Phio Pharmaceuticals has showed a +0% increase.
When is the next Phio Pharmaceuticals earnings date?▼
Phio Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Phio Pharmaceuticals earnings last quarter?▼
44R0.MU earnings for the last quarter are -0.13 EUR per share, whereas the estimation was -0.29 EUR resulting in a +55.88% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Phio Pharmaceuticals have?▼
As of May 06, 2026, the company has 5 employees.
In which sector is Phio Pharmaceuticals located?▼
Phio Pharmaceuticals operates in the Health & Wellness sector.
When did Phio Pharmaceuticals complete a stock split?▼
Phio Pharmaceuticals has not had any recent stock splits.
Where is Phio Pharmaceuticals headquartered?▼
Phio Pharmaceuticals is headquartered in King Of Prussia, United States.